Loading data for NNVC — first visit, this takes a few seconds.

알림

NanoViricides Inc. (NNVC)

NYSE American: NNVC · 실시간 가격 · USD

1.35

-0.01 (-0.74%)

종가 기준: Aug 18, 2026, 8:00 PM

1.34

-0.74%

프리마켓: 4:24 AM

-0.74% (1D)

데이터 없음

매수호가	n/a
시가총액	34.42M
매출 (ttm)	n/a
순이익 (ttm)	-8.09M
베타	1.69
EPS (ttm)	-0.44
P/E (ttm)	n/a
선행 P/E	-3.86
P/B (ttm)	3.19
P/S (ttm)	n/a
Earnings Date	n/a

매도호가	n/a
거래량	256,381
평균 거래량 (20일)	907,890
시가	1.35
전일 종가	1.36
일중 범위	1.32 - 1.38
52주 범위	0.85 - 2.23
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

NNVC 소개

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections com...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Oct 26, 2005

직원 수 7

상장 거래소 NYSE American

티커 NNVC

웹사이트 https://www.nanoviricides.com

전체 기업 정보

재무 실적

2025년 NanoViricides의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -9.47M로, 14.14% 증가했습니다.

재무제표

어닝 서프라이즈

NanoViricides가 May 15, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -0.09 예상치 하회 -0.01, 및 43.75% 전년 대비 성장.

뉴스

1개월 전 · Stocktwits

NNVC Stock In The Limelight After This Analyst Sees A 350% Upside Potential – Everything To Know About Its Experimental Drug For Ebola

The biotech firm said it is progressing towards a Phase II clinical trial of its antiviral drug NV-387 for the Bundibugyo Ebola outbreak in the Democratic Republic of Congo.

1개월 전 · IPO-Edge.com

REPLAY: Fireside Chat with NanoViricides President & Exec. Chairman Anil R. Diwan

Watch Fireside Chat Below, or Click HERE: Exec Edge hosted a fireside chat with NanoViricides, Inc. (NYSE: NNVC) President and Executive Chairman Anil R. Diwan, PhD, moderated by IPO Edge […]

3개월 전 · Proactive

NanoViricides closes $2M direct offering

NanoViricides (NYSE-A:NNVC) announced the closing of its previously disclosed registered direct offering, raising about $2 million in gross proceeds before fees and expenses. The clinical-stage antivi...

3개월 전 · Proactive

NanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreak

NanoViricides (NYSE-A:NNVC), the US clinical-stage drugmaker, has said its lead drug candidate NV-387 could be effective against the Bundibugyo strain of Ebola virus that has prompted the World Health...

3개월 전 · Proactive

NanoViricides to raise $2M in registered direct offering

NanoViricides (NYSE-A:NNVC) said it has entered into a securities purchase agreement with a single institutional investor for gross proceeds of approximately $2 million in a registered direct offering...

2 페이지 중 1

NanoViricides Inc. (NNVC)